Evidence map›Paper›PMID 27212031›Full record

ArticleOncogene2016

Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.

G B Martinelli, D Olivari, A D Re Cecconi, L Talamini, L Ottoboni, S H Lecker, C Stretch, V E Baracos, O F Bathe, A Resovi and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

G B MartinelliDepartment of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
D OlivariDepartment of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
A D Re CecconiDepartment of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
L TalaminiDepartment of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
L OttoboniSan Raffaele Scientific Institute, INSpe, Milan, Italy.
S H LeckerBeth Israel Deaconess Center, Boston, MA, USA.
C StretchDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
V E BaracosDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
O F BatheDepartment of Surgery and Oncology, University of Calgary, Calgary, Alberta, Canada.
A ResoviDepartment of Oncology, Tumor Angiogenesis Unit, IRCCS - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
R GiavazziDepartment of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
L CervoDepartment of Neuroscience, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
R PiccirilloDepartment of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
Mario Negri Institute for Pharmacological Research · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Alberta · CASan Raffaele University of Rome · ITUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (α, β, γ) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1α or SDF1β had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time- and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.

Indexed as

Muscular AtrophySignal TransductionAnimalsBenzylaminesBiomarkersCachexiaChemokine CXCL12CyclamsCytokinesDisease Models, AnimalFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticHeterocyclic CompoundsHumansBenzylaminesBiomarkersChemokine CXCL12CyclamsCytokinesHeterocyclic CompoundsIndolesplerixaforPyrrolesReceptors, CXCR4Sunitinib

Identifiers

PMID27212031
OpenAlexW2401027603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.